ARCHIVES

NTP Panel Agrees PBB Carcinogenic, Two Asbestos Varieties Are Not

This article is from The Cancer Letter archive.

Vol. 07 No. 27 | July 3, 1981

Download PDF Visit The Full Archive

Related Articles

ELM’s CHOP-DS Aims For 15% Of Patients

September 13, 1985

Counter-Point: George Sledge Responds To Berry’s Letter: Neoadjuvant Doesn’t Predict Adjuvant In Breast Cancer

July 11, 2014

Nominations Open for Bristol-Myers $25,000

September 29, 1978

Genentech Reps Not Welcome: Hospitals Urge Drug Maker to Reverse Policy On Supplying Avastin, Rituxan, & Herceptin

October 17, 2014

Randomized Trial Finds Sunscreen Use Cuts Risk Of Developing Melanoma

December 31, 2010

Troubles of Two Landmark Cancer Drugs, Celebrex and Iressa, Likely to Shape cancer Prevention, FDA Policy. FDA Mulls Withdrawal of Iressa.

January 7, 2005